JP2013504537A - Ampk活性化因子としてのピロロピリジン誘導体 - Google Patents

Ampk活性化因子としてのピロロピリジン誘導体 Download PDF

Info

Publication number
JP2013504537A
JP2013504537A JP2012528352A JP2012528352A JP2013504537A JP 2013504537 A JP2013504537 A JP 2013504537A JP 2012528352 A JP2012528352 A JP 2012528352A JP 2012528352 A JP2012528352 A JP 2012528352A JP 2013504537 A JP2013504537 A JP 2013504537A
Authority
JP
Japan
Prior art keywords
hydroxy
dihydro
pyrrolo
oxo
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012528352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504537A5 (enExample
Inventor
オリビエ、ミルゲ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of JP2013504537A publication Critical patent/JP2013504537A/ja
Publication of JP2013504537A5 publication Critical patent/JP2013504537A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
JP2012528352A 2009-09-10 2010-09-08 Ampk活性化因子としてのピロロピリジン誘導体 Pending JP2013504537A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0915892.4 2009-09-10
GBGB0915892.4A GB0915892D0 (en) 2009-09-10 2009-09-10 Compounds
PCT/EP2010/063196 WO2011029855A1 (en) 2009-09-10 2010-09-08 Pyrrolo-pyridine derivatives as activators of ampk

Publications (2)

Publication Number Publication Date
JP2013504537A true JP2013504537A (ja) 2013-02-07
JP2013504537A5 JP2013504537A5 (enExample) 2013-10-24

Family

ID=41228136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528352A Pending JP2013504537A (ja) 2009-09-10 2010-09-08 Ampk活性化因子としてのピロロピリジン誘導体

Country Status (5)

Country Link
US (1) US20120172333A1 (enExample)
EP (1) EP2475660A1 (enExample)
JP (1) JP2013504537A (enExample)
GB (1) GB0915892D0 (enExample)
WO (1) WO2011029855A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016031842A1 (ja) * 2014-08-27 2016-03-03 塩野義製薬株式会社 Ampk活性化作用を有するアザインドール誘導体

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2486631A (en) * 2010-12-01 2012-06-27 Univ Sheffield Phenol/quinone boronic acids/esters and method of preparation thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2928474B1 (en) 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
JP6306607B2 (ja) 2012-12-21 2018-04-04 ケモセントリックス,インコーポレイティド ジアゾールアミド
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
EP4066832A4 (en) * 2019-11-14 2024-01-03 Zincure Corp. Pharmaceutical composition for treating multiple sclerosis on basis of ampk inhibitory function and zinc homeostasis control function
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
US11857346B2 (en) 2021-05-25 2024-01-02 Warsaw Orthopedic, Inc. Systems and methods for real-time monitoring of bone correction
AU2022391025A1 (en) 2021-11-19 2024-06-06 The Brigham And Women's Hospital, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033502A1 (en) * 2001-10-16 2003-04-24 Celltech R & D Limited Bicyclic oxopyridine and oxopyrimidine derivatives
US20030096813A1 (en) * 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
US20050038068A1 (en) * 2003-05-16 2005-02-17 Iyengar Rajesh R. Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2008137060A1 (en) * 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
WO2009076631A1 (en) * 2007-12-12 2009-06-18 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009100130A1 (en) * 2008-02-04 2009-08-13 Mercury Therapeutics, Inc. Ampk modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
FR2888848B1 (fr) * 2005-07-22 2007-09-28 Sanofi Aventis Sa Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096813A1 (en) * 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
WO2003033502A1 (en) * 2001-10-16 2003-04-24 Celltech R & D Limited Bicyclic oxopyridine and oxopyrimidine derivatives
US20050038068A1 (en) * 2003-05-16 2005-02-17 Iyengar Rajesh R. Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2008137060A1 (en) * 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
WO2009076631A1 (en) * 2007-12-12 2009-06-18 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009100130A1 (en) * 2008-02-04 2009-08-13 Mercury Therapeutics, Inc. Ampk modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014034124; Elbannany, Afaf A. A.; Ibrahim, Laila I.: 'Synthesis of pyrrole, pyrrolidone, pyrrolo[3,4-c]pyrazole, pyrrolo[3,2-b]pyridine and pyrrolo[3,2-b]' Heterocycles 27(9), 1988, 2071-2075 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016031842A1 (ja) * 2014-08-27 2016-03-03 塩野義製薬株式会社 Ampk活性化作用を有するアザインドール誘導体
JPWO2016031842A1 (ja) * 2014-08-27 2017-06-22 塩野義製薬株式会社 Ampk活性化作用を有するアザインドール誘導体
US9980948B2 (en) 2014-08-27 2018-05-29 Shionogi & Co., Ltd. Azaindole derivative having AMPK-activating activity

Also Published As

Publication number Publication date
US20120172333A1 (en) 2012-07-05
GB0915892D0 (en) 2009-10-14
EP2475660A1 (en) 2012-07-18
WO2011029855A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
US20120172333A1 (en) Pyrrolo-pyridine derivatives as activators of ampk
CN104395319B (zh) 用作ampk的活化剂的噻吩并吡啶酮衍生物
CN103517896B (zh) 喹啉酮衍生物
AU2007292155B2 (en) Imidazole derivative
AU2022219987A1 (en) Cdk inhibitors and methods of use thereof
TWI469977B (zh) 7-苯氧基唍羧酸衍生物
TW201718597A (zh) Hpk1抑制劑及其使用方法
US10548883B2 (en) Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor
EP3426243B1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2012021615A1 (en) Heteroaryls and uses thereof
US20130165472A1 (en) Heteroaryls and uses thereof
MX2007013154A (es) Compuestos heterociclicos fusionados.
CA2988502A1 (en) Nuclear receptor modulators
MX2013006054A (es) Compuestos de triazolopiridina.
JP2021514939A (ja) ヘテロ二環式有機酸およびその塩類
JP2014507453A (ja) 1H−ピロロ[3,2−d]ピリミジンジオン誘導体
CN119487006A (zh) 作为pge2受体拮抗剂的酰胺化合物
JP2013525466A (ja) Ampkのアクチベーターとして用いられるピロロ[3,2−d]ピリミジン−3−イル誘導体
CA2508319A1 (en) Jnk inhibitors
EP3921310B1 (en) New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators
CN103313707A (zh) 二苯基-胺衍生物的用途、合成方法及药物组合物
KR20230061482A (ko) 인터페론 유전자 자극제 (stimulator of interferon genes)(STING) 의 작용제들
TW202214634A (zh) 雜環化合物及其衍生物
CN102558185A (zh) 吡啶并吡咯三嗪化合物、其制备方法和用途
CN101166729B (zh) 稠合的杂环化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140814

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150123